Clinical Trials Browser

Phase 2/3 × Active not recruiting × osimertinib × Clear all

NCT05020769 2025-09-26

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung